A balance of interleukin-12 and -23 in cancer

Trends in Immunology

Volumn 34, Issue 11, 2013, Pages 548-555

  Ngiow, Shin Foong ^a   Teng, Michele W L ^a,b   Smyth, Mark J ^a,b  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Autoimmunity; Cancer; Cytokine; Inflammation

Indexed keywords

3 METHYLCHOLANTHRENE; ANTINEOPLASTIC AGENT; BRIAKINUMAB; CD40 LIGAND; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 12 ANTIBODY; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 22; INTERLEUKIN 23; INTERLEUKIN 23 ANTIBODY; INTERLEUKIN 23P19; STAT3 PROTEIN; STAT4 PROTEIN; USTEKINUMAB;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIBIOTIC THERAPY; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; B CELL LYMPHOMA; BIOLOGICAL THERAPY; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER CONTROL; CANCER INHIBITION; CANCER PATIENT; CANCER PREVENTION; CARCINOGENESIS; CELL DEATH; CELLULAR STRESS RESPONSE; CLINICAL OBSERVATION; COLON CARCINOMA; COLON POLYPOSIS; COLORECTAL CANCER; CROHN DISEASE; CYTOKINE PRODUCTION; DRUG SAFETY; FIBROSARCOMA; FOLLOW UP; GENETIC ASSOCIATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; IN VITRO STUDY; LIVER CELL CARCINOMA; LONG TERM CARE; LUNG CARCINOMA; LUNG NON SMALL CELL CANCER; MELANOMA B16; MOUTH SQUAMOUS CELL CARCINOMA; NATURAL KILLER CELL; NATURAL KILLER T CELL; NEOPLASM; NONHUMAN; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; PHOTOTHERAPY; PROSTATE CARCINOMA; PROTEIN EXPRESSION; PSORIASIS; PSORIATIC ARTHRITIS; REGULATORY T LYMPHOCYTE; REVIEW; SKIN PAPILLOMA; SYSTEMIC THERAPY; TH17 CELL; TUMOR CELL LINE; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; TUMOR PROMOTION; ULCERATIVE COLITIS; WILD TYPE;

AUTOIMMUNITY; CANCER; CYTOKINE; INFLAMMATION;

ANIMALS; ANTIBODIES, MONOCLONAL; AUTOIMMUNE DISEASES; CARCINOGENESIS; HUMANS; INTERLEUKIN-12; INTERLEUKIN-23; NEOPLASMS;

EID: 84886952640     PISSN: 14714906     EISSN: 14714981     Source Type: Journal    
DOI: 10.1016/j.it.2013.07.004     Document Type: Review

References (99)

1. Vignali D.A., Kuchroo V.K. IL-12 family cytokines: immunological playmakers. Nat. Immunol. 2012, 13:722-728.
2. Oppmann B., et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000, 13:715-725.
3. Kastelein R.A., et al. Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation. Annu. Rev. Immunol. 2007, 25:221-242.
4. Guo L., et al. Cytokine-induced cytokine production by conventional and innate lymphoid cells. Trends Immunol. 2012, 33:598-606.
5. Pearson C., et al. Lymphoid microenvironments and innate lymphoid cells in the gut. Trends Immunol. 2012, 33:289-296.
6. Awasthi A., et al. Cutting edge: IL-23 receptor gfp reporter mice reveal distinct populations of IL-17-producing cells. J. Immunol. 2009, 182:5904-5908.
7. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. 2003, 3:133-146.
8. Nastala C.L., et al. Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. J. Immunol. 1994, 153:1697-1706.
9. Cao X., et al. Interleukin 12 stimulates IFN-gamma-mediated inhibition of tumor-induced regulatory T-cell proliferation and enhances tumor clearance. Cancer Res. 2009, 69:8700-8709.
10. Dunn G.P., et al. Interferons, immunity and cancer immunoediting. Nat. Rev. Immunol. 2006, 6:836-848.
11. Colombo M.P., Trinchieri G. Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev. 2002, 13:155-168.
12. Kerkar S.P., et al. IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. J. Clin. Invest. 2011, 121:4746-4757.
13. Eisenring M., et al. IL-12 initiates tumor rejection via lymphoid tissue-inducer cells bearing the natural cytotoxicity receptor NKp46. Nat. Immunol. 2010, 11:1030-1038.
14. Smyth M.J., et al. Differential tumor surveillance by natural killer (NK) and NKT cells. J. Exp. Med. 2000, 191:661-668.
15. Kaplan D.H., et al. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:7556-7561.
16. Hafner M., et al. Interleukin-12 activates NK cells for IFN-gamma-dependent and NKT cells for IFN-gamma-independent antimetastatic activity. Eur. Cytokine Netw. 1999, 10:541-548.
17. Perry L.L., et al. Immunity to Chlamydia trachomatis is mediated by T helper 1 cells through IFN-gamma-dependent and -independent pathways. J. Immunol. 1997, 158:3344-3352.
18. Wang Z.E., et al. Interferon gamma-independent effects of interleukin 12 administered during acute or established infection due to Leishmania major. Proc. Natl. Acad. Sci. U.S.A. 1994, 91:12932-12936.
19. Helmby H., Grencis R.K. IFN-gamma-independent effects of IL-12 during intestinal nematode infection. J. Immunol. 2003, 171:3691-3696.
20. Langowski J.L., et al. IL-23 promotes tumour incidence and growth. Nature 2006, 442:461-465.
21. Street S.E., et al. Suppression of lymphoma and epithelial malignancies effected by interferon gamma. J. Exp. Med. 2002, 196:129-134.
22. Airoldi I., et al. Lack of Il12rb2 signaling predisposes to spontaneous autoimmunity and malignancy. Blood 2005, 106:3846-3853.
23. Korn T., et al. IL-17 and Th17 Cells. Annu. Rev. Immunol. 2009, 27:485-517.
24. McKenzie B.S., et al. Understanding the IL-23-IL-17 immune pathway. Trends Immunol. 2006, 27:17-23.
25. Rubino S.J., et al. Innate IL-17 and IL-22 responses to enteric bacterial pathogens. Trends Immunol. 2012, 33:112-118.
26. McGeachy M.J., et al. The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo. Nat. Immunol. 2009, 10:314-324.
27. Lee Y., et al. Induction and molecular signature of pathogenic TH17 cells. Nat. Immunol. 2012, 13:991-999.
28. Cella M., et al. A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity. Nature 2009, 457:722-725.
29. Colonna M. Interleukin-22-producing natural killer cells and lymphoid tissue inducer-like cells in mucosal immunity. Immunity 2009, 31:15-23.
30. Paget C., et al. Interleukin-22 is produced by invariant natural killer T lymphocytes during influenza A virus infection: potential role in protection against lung epithelial damages. J. Biol. Chem. 2012, 287:8816-8829.
31. Sutton C.E., et al. Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Th17 responses and autoimmunity. Immunity 2009, 31:331-341.
32. Sender L.Y., et al. CD40 ligand-triggered human dendritic cells mount interleukin-23 responses that are further enhanced by danger signals. Mol. Immunol. 2010, 47:1255-1261.
33. Uhlig H.H., et al. Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology. Immunity 2006, 25:309-318.
34. Bosmann M., et al. CD11c+ alveolar macrophages are a source of IL-23 during LPS-induced acute lung injury. Shock 2013, 39:447-452.
35. Gerosa F., et al. Differential regulation of interleukin 12 and interleukin 23 production in human dendritic cells. J. Exp. Med. 2008, 205:1447-1461.
36. Schnurr M., et al. Extracellular nucleotide signaling by P2 receptors inhibits IL-12 and enhances IL-23 expression in human dendritic cells: a novel role for the cAMP pathway. Blood 2005, 105:1582-1589.
37. Schwarz H., et al. TLR8 and NOD signaling synergistically induce the production of IL-1beta and IL-23 in monocyte-derived DCs and enhance the expression of the feedback inhibitor SOCS2. Immunobiology 2013, 218:533-542.
38. Dennehy K.M., et al. Reciprocal regulation of IL-23 and IL-12 following co-activation of Dectin-1 and TLR signaling pathways. Eur. J. Immunol. 2009, 39:1379-1386.
39. Sheikh S.Z., et al. Cutting edge: IFN-gamma is a negative regulator of IL-23 in murine macrophages and experimental colitis. J. Immunol. 2010, 184:4069-4073.
40. Sieve A.N., et al. A novel immunoregulatory function for IL-23: Inhibition of IL-12-dependent IFN-gamma production. Eur. J. Immunol. 2010, 40:2236-2247.
41. Grivennikov S.I., et al. Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature 2012, 491:254-258.
42. Yu H., et al. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer 2009, 9:798-809.
43. Grivennikov S.I., et al. Immunity, inflammation, and cancer. Cell 2010, 140:883-899.
44. Ausiello C.M., et al. 60-kDa heat shock protein of Chlamydia pneumoniae promotes a T helper type 1 immune response through IL-12/IL-23 production in monocyte-derived dendritic cells. Microbes Infect. 2006, 8:714-720.
45. Sheibanie A.F., et al. Prostaglandin E2 induces IL-23 production in bone marrow-derived dendritic cells. FASEB J. 2004, 18:1318-1320.
46. Iwasaki K., et al. Prostaglandin E2 downregulates interleukin-12 production through EP4 receptors in human monocytes stimulated with lipopolysaccharide from Actinobacillus actinomycetemcomitans and interferon-gamma. Oral Microbiol. Immunol. 2003, 18:150-155.
47. Ghiringhelli F., et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat. Med. 2009, 15:1170-1178.
48. Teng M.W., et al. IL-23 suppresses innate immune response independently of IL-17A during carcinogenesis and metastasis. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:8328-8333.
49. Wu S., et al. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat. Med. 2009, 15:1016-1022.
50. Kortylewski M., et al. Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. Cancer Cell 2009, 15:114-123.
51. Cornelissen F., et al. Activation and effector functions of human RORC+ innate lymphoid cells. Curr. Opin. Immunol. 2011, 23:361-367.
52. Eyerich S., et al. IL-17 and IL-22: siblings, not twins. Trends Immunol. 2010, 31:354-361.
53. Huber S., et al. IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine. Nature 2012, 491:259-263.
54. Jiang R., et al. IL-22 is related to development of human colon cancer by activation of STAT3. BMC Cancer 2013, 13:59.
55. Schreiber R.D., et al. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011, 331:1565-1570.
56. Koebel C.M., et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 2007, 450:903-907.
57. Teng M.W., et al. Opposing roles for IL-23 and IL-12 in maintaining occult cancer in an equilibrium state. Cancer Res. 2012, 72:3987-3996.
58. Jantschitsch C., et al. IL-12 and IL-23 affect photocarcinogenesis differently. J. Invest. Dermatol. 2012, 132:1479-1486.
59. Majewski S., et al. IL-23 antagonizes UVR-induced immunosuppression through two mechanisms: reduction of UVR-induced DNA damage and inhibition of UVR-induced regulatory T cells. J. Invest. Dermatol. 2010, 130:554-562.
60. Li J., et al. Interleukin 23 promotes hepatocellular carcinoma metastasis via NF-kappa B induced matrix metalloproteinase 9 expression. PLoS ONE 2012, 7:e46264.
61. Gangemi S., et al. Clinical significance of circulating interleukin-23 as a prognostic factor in breast cancer patients. J. Cell. Biochem. 2012, 113:2122-2125.
62. Ljujic B., et al. Elevated serum level of IL-23 correlates with expression of VEGF in human colorectal carcinoma. Arch. Med. Res. 2010, 41:182-189.
63. He S., et al. Distribution and clinical significance of th17 cells in the tumor microenvironment and peripheral blood of pancreatic cancer patients. Int. J. Mol. Sci. 2011, 12:7424-7437.
64. Fukuda M., et al. IL-23 promotes growth and proliferation in human squamous cell carcinoma of the oral cavity. Int. J. Oncol. 2010, 36:1355-1365.
65. Fukuda M., et al. Expression of interleukin-23 and its receptors in human squamous cell carcinoma of the oral cavity. Mol. Med. Rep. 2010, 3:89-93.
66. Baird A.M., et al. IL-23 is pro-proliferative, epigenetically regulated and modulated by chemotherapy in non-small cell lung cancer. Lung Cancer 2013, 79:83-90.
67. Xu Y., et al. IL-23R polymorphisms, HBV infection, and risk of hepatocellular carcinoma in a high-risk Chinese population. J. Gastroenterol. 2013, 48:125-131.
68. Chu H., et al. Potentially functional polymorphisms in IL-23 receptor and risk of esophageal cancer in a Chinese population. Int. J. Cancer 2012, 130:1093-1097.
69. Chen J., et al. A nonsynonymous polymorphism in IL23R gene is associated with risk of gastric cancer in a Chinese population. Mol. Carcinog. 2010, 49:862-868.
70. Qian X., et al. Potentially functional polymorphism in IL-23 receptor and risk of acute myeloid leukemia in a Chinese population. PLoS ONE 2013, 8:e55473.
71. Chiyo M., et al. Antitumor effects produced by transduction of dendritic cells-derived heterodimeric cytokine genes in murine colon carcinoma cells. Anticancer Res. 2004, 24:3763-3767.
72. Hu P., et al. Expression of interleukins-23 and 27 leads to successful gene therapy of hepatocellular carcinoma. Mol. Immunol. 2009, 46:1654-1662.
73. Oniki S., et al. Interleukin-23 and interleukin-27 exert quite different antitumor and vaccine effects on poorly immunogenic melanoma. Cancer Res. 2006, 66:6395-6404.
74. Kaiga T., et al. Systemic administration of IL-23 induces potent antitumor immunity primarily mediated through Th1-type response in association with the endogenously expressed IL-12. J. Immunol. 2007, 178:7571-7580.
75. Reay J., et al. The antitumor effects of adenoviral-mediated, intratumoral delivery of interleukin 23 require endogenous IL-12. Cancer Gene Ther. 2012, 19:135-143.
76. Hu J., et al. Induction of potent antitumor immunity by intratumoral injection of interleukin 23-transduced dendritic cells. Cancer Res. 2006, 66:8887-8896.
77. Yuan X., et al. Interleukin-23-expressing bone marrow-derived neural stem-like cells exhibit antitumor activity against intracranial glioma. Cancer Res. 2006, 66:2630-2638.
78. Overwijk W.W., et al. Immunological and antitumor effects of IL-23 as a cancer vaccine adjuvant. J. Immunol. 2006, 176:5213-5222.
79. Jin H.T., et al. Adenovirus-mediated gene transfer of interleukin-23 shows prophylactic but not therapeutic antitumor effects. Cancer Gene Ther. 2008, 15:693-702.
80. Cocco C., et al. Interleukin-23 acts as antitumor agent on childhood B-acute lymphoblastic leukemia cells. Blood 2010, 116:3887-3898.
81. Cocco C., et al. Complementary IL-23 and IL-27 anti-tumor activities cause strong inhibition of human follicular and diffuse large B-cell lymphoma growth in vivo. Leukemia 2012, 26:1365-1374.
82. Wolf A.M., et al. High IL-12 p35 and IL-23 p19 mRNA expression is associated with superior outcome in ovarian cancer. Gynecol. Oncol. 2010, 118:244-250.
83. Langowski J.L., et al. Swords into plowshares: IL-23 repurposes tumor immune surveillance. Trends Immunol. 2007, 28:207-212.
84. Li J., et al. Interleukin 23 regulates proliferation of lung cancer cells in a concentration-dependent way in association with the interleukin-23 receptor. Carcinogenesis 2013, 34:658-666.
85. Benson J.M., et al. Therapeutic targeting of the IL-12/23 pathways: generation and characterization of ustekinumab. Nat. Biotechnol. 2011, 29:615-624.
86. Gordon K.B., et al. Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials. J. Am. Acad. Dermatol. 2012, 66:742-751.
87. Kimball A.B., et al. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study. J. Eur. Acad. Dermatol. Venereol. 2012, 10.1111/jdv.12046.
88. Reich K., et al. A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis. N. Engl. J. Med. 2011, 365:1586-1596.
89. Gordon K.B., et al. A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasis. J. Invest. Dermatol. 2012, 132:304-314.
90. Langley R.G., et al. Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis. J. Eur. Acad. Dermatol. Venereol. 2012, 10.1111/j.1468-3083.2012.04705.x.
91. Reich K., et al. An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up. J. Drugs Dermatol. 2012, 11:300-312.
92. Young L., Czarnecki D. The rapid onset of multiple squamous cell carcinomas in two patients commenced on ustekinumab as treatment of psoriasis. Australas. J. Dermatol. 2012, 53:57-60.
93. Naldi L. Malignancy concerns with psoriasis treatments using phototherapy, methotrexate, cyclosporin, and biologics: facts and controversies. Clin. Dermatol. 2010, 28:88-92.
94. Laurence A., O'Shea J.J. T(H)-17 differentiation: of mice and men. Nat. Immunol. 2007, 8:903-905.
95. Teng M.W., et al. Anti-IL-23 monoclonal antibody synergizes in combination with targeted therapies or IL-2 to suppress tumor growth and metastases. Cancer Res. 2011, 71:2077-2086.
96. Shan B.E., et al. Antitumor activity and immune enhancement of murine interleukin-23 expressed in murine colon carcinoma cells. Cell. Mol. Immunol. 2006, 3:47-52.
97. Wang Y.Q., et al. Induction of systemic immunity by expression of interleukin-23 in murine colon carcinoma cells. Int. J. Cancer 2003, 105:820-824.
98. Liu L., et al. Antitumor effects and immunoregulation mechanisms of IL-23 gene in mouse mammary cancer mediated by retrovirus. Cell. Immunol. 2009, 258:181-187.
99. Lo C.H., et al. Antitumor and antimetastatic activity of IL-23. J. Immunol. 2003, 171:600-607.